Xeris Biopharma Holdings, Inc.
XERS
Rank in Stocks
#4780
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company,... Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Share Price
$15.86
Last synced: 2026-11-09
Market Cap
$2.89B
Change (1 day)
4.34%
Change (1 year)
120.89%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xeris Biopharma Holdings, Inc. (XERS)
Category
Healthcare
Operating Margin for Xeris Biopharma Holdings, Inc. (XERS)
Operating Margin as of November 2026 TTM: 10.91%
According to Xeris Biopharma Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is 10.91%. At the end of 2025 the company had an operating margin of 8.53%.
Operating Margin history for Xeris Biopharma Holdings, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 10.91% | 27.90% |
| 2025 | 8.53% | -151.48% |
| 2024 | -16.57% | -38.29% |
| 2023 | -26.85% | -63.87% |
| 2022 | -74.32% | -68.00% |
| 2021 | -232.22% | -43.20% |
| 2020 | -408.84% | -90.91% |
| 2019 | -4,495.96% | 86.75% |
| 2018 | -2,407.46% | 40.67% |
| 2017 | -1,711.38% | 39.05% |
| 2016 | -1,230.79% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -116.62% |
US
|
|
| 38.59% | -96.46% |
US
|
|
| -149.01% | -113.66% |
US
|
|
| 25.57% | -97.66% |
AU
|
|
| 31.23% | -97.14% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Xeris Biopharma Holdings, Inc.'s operating margin
What is Xeris Biopharma Holdings, Inc.'s operating margin?
Xeris Biopharma Holdings, Inc.'s operating margin is 10.91%, as of Nov 2026.
What was Xeris Biopharma Holdings, Inc.'s operating margin in 2025?
In 2025, Xeris Biopharma Holdings, Inc.'s operating margin was 8.53%, compared with -16.57% in 2024.
How has Xeris Biopharma Holdings, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Xeris Biopharma Holdings, Inc.'s operating margin was highest in 2025 (8.53%) and lowest in 2020 (-408.84%).
How does Xeris Biopharma Holdings, Inc.'s operating margin compare with similar companies?
Xeris Biopharma Holdings, Inc.'s operating margin (10.91%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.